



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/633,680	08/05/2003		Craig A. Rosen	PZ026P1C2	5485	
22195	7590	12/29/2005		EXAM	EXAMINER	
		SCIENCES INC	SAOUD, CHRISTINE J			
INTELLECTUAL PROPERTY DEPT. 14200 SHADY GROVE ROAD				ART UNIT	PAPER NUMBER	
ROCKVILLE, MD 20850				1647		

DATE MAILED: 12/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Offi Astion Comments	10/633,680	ROSEN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Christine J. Saoud	1647					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on							
	action is non-final.						
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
• •	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-24</u> is/are pending in the application.	Claim(s) <u>1-24</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)☐' Claim(s) is/are rejected.	]' Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.							
8) Claim(s) <u>1-24</u> are subject to restriction and/or e	election requirement.						
Application Papers							
9) The specification is objected to by the Examine	r.	•					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
2) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau	· •	o in this National Stage					
* See the attached detailed Office action for a list of	, ,,,	d.					
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate atent Application (PTO-152)					

Page 2

Art Unit: 1647

Application/Control Number: 10/633,680

## **DETAILED ACTION**

## Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10, 14-15, and 21, drawn to polynucleotides, vectors, host cells and methods of making a polypeptide, classified in at least class 435, subclass 69.4, for example.
- II. Claims 11-12, and 16 drawn to a polypeptide, classified in class 530, subclass 399, for example.
- III. Claim 13, drawn to an antibody to a polypeptide, classified in class 530, subclass 387.1, for example.
- IV. Claim 17, drawn to a method of treatment by administration of the polypeptide, classified in class 514, subclass 2, for example.
- V. Claim 24, drawn to a method of treatment by administration of the polynucleotide, classified in class 514, subclass 44, for example.
- VI. Claim 18, drawn to a method of detecting a mutation in DNA, classified in class 536, subclass 24.3, for example.
- VII. Claim 19, drawn to a method of detecting a polypeptide, classified in class 435, subclass 7.1, for example.
- VIII. Claim 20, drawn to a method of identifying a binding partner, classified in class 436, subclass 501, for example.
- IX. Claim 22, drawn to a method of identifying an activity in an assay, classified in class 435, subclass 4, for example.
- X. Claim 23, drawn to a compound of unidentified constitution, class undeterminable, subclass undeterminable.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process

Art Unit: 1647

for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polynucleotides of Group I could be used in an entirely different method, such as in a method of detection of the polynucleotide in a sample, rather than in a method of making the polypeptide.

Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptide of Group II could be used for an entirely different purpose such as in the method of Group VIII, rather than for the production of antibodies of Group III.

Inventions I-III are also are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to chemically different compounds which can be made and used without each other. Furthermore, the inventions of Groups I-III lack a common utility which is based upon a common special technical feature which is disclosed as being responsible for the common utility.

Inventions (I-III) and X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of

Art Unit: 1647

operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to chemically different compounds which can be made and used without each other. The structure of the compound of Group X is not defined, however, it would appear that it lacks a common utility which is based upon a common special technical feature (structure) which is disclosed as being responsible for the common utility.

Inventions II and (IV, VII and VIII) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides of Group II could be used in an entirely different manner, such as in a method of making antibodies rather than in the methods of Groups IV, VII, and VIII.

Inventions I and (IV, VII-VIII) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects.

(MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not required one for the other in that the DNA Group I is not required for the methods of Groups (IV, VII-VIII).

Inventions I and (V-VI, and IX) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially

different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the DNA of Group I could be used in an entirely different method, such as in the recombinant production of the polypeptide rather than in the methods of Groups (V-VI, and IX).

Inventions II and (V-VI, and IX) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects.

(MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not required one for the other in that the polypeptide of Group II is not required for the methods of Groups (V-VI, and IX).

Inventions III and VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibodies of Group III could be used in an entirely different manner, such as in the purification of the polypeptide rather than in the method of Group VII.

Inventions III and (IV-VI and VIII-IX) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions

Art Unit: 1647

are not required one for the other in that the antibody of Group III is not required for the methods of Groups (IV-VI and VIII-IX).

Inventions IV-IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to methods which have different method steps, starting materials and goals.

Inventions (IV-IX) and X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects.

(MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to methods (Groups IV-IX) which do not require the compound of Group X and which are not disclosed as capable of use

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and the necessity for non-coextensive literature searches, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

The claims of Group I-X are drawn to a multitude of nucleic acids (SEQ ID NO:Y), polypeptides (SEQ ID NO:X), antibodies thereto and methods which use these compounds. This constitutes recitation of an implied, mis-joined Markush group that contains multiple, independent and distinct inventions. Each of the different nucleic acids/ polypeptides/antibodies/ and methods of use are independent and distinct because no common structural or functional properties are shared. Accordingly, these claims are subject to restriction under 35 U.S.C. § 121.

Upon election of one of Groups I-X, Applicant is additionally required to elect a single nucleic acid, polypeptide, or antibody. This requirement is not to be construed as a requirement for an election of species, since each of the compounds recited in alternative form is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine J. Saoud whose telephone number is 571-272-0891. The examiner can normally be reached on mttr, 8:00-2:00.

Application/Control Number: 10/633,680 Page 8

Art Unit: 1647

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CHRISTINE J. SAOUD PRIMARY EXAMINER Christine J. Saoud